Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent Progress in CDK4/6 Inhibitors and PROTACs

13 Dec 2023

Abstract excerpt

Cell division in eukaryotes is a highly regulated process that is critical to the life of a cell. Dysregulated cell proliferation, often driven by anomalies in cell Cyclin-dependent kinase (CDK) activation, is a key pathological mechanism in cancer. Recently, selective CDK4/6 inhibitors have shown clinical success, particularly in treating advanced-stage estrogen receptor (ER)-positive and human epidermal growth...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to HER2/EGFR in Cancer Research
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38138549
DOI: 10.3390/molecules28248060

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent Progress in CDK4/6 Inhibitors and PROTACsPMID 38138549Read ↗

Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent KinaseSemantic proximity Read ↗

Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer TreatmentSemantic proximity Read ↗

Exploiting targeted degradation of cyclins and cyclin-dependent kinases for cancer therapeutics: a reviewSemantic proximity Read ↗

Current progress and novel strategies that target CDK12 for drug discovery.Semantic proximity Read ↗

Cyclin-dependent kinasesSemantic proximity Read ↗

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developmentsSemantic proximity Read ↗

Structural insights into the functional diversity of the CDK–cyclin familySemantic proximity Read ↗

CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer AgentsSemantic proximity Read ↗

CDK4 and CDK6 kinases: From basic science to cancer therapySemantic proximity Read ↗

Cyclin-dependent protein kinases and cell cycle regulation in biology and diseaseSemantic proximity Read ↗

Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An UpdateSemantic proximity Read ↗

Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera DegradersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.